醒脑静联合依达拉奉对急性脑梗死患者早期神经功能恶化的治疗效果

Efficacy of Xingnaojing combined with edaravone in treating patients with acute cerebral infarction and early neurologic deterioration

目的探讨醒脑静联合依达拉奉治疗急性脑梗死(ACI)早期神经功能恶化的效果。方法 ACI早期神经功能恶化患者80例随机均分为两组,均给予常规综合治疗;对照组加用醒脑静与依达拉奉静脉滴注,疗程为1个月。采用NIHSS评分、Barthel指数(BI)和道格拉斯昏迷评分(GCS)评估疗效。结果治疗后,两组神经功能均有明显改善(P<0.05)。观察组治疗后的GCS评分、NIHSS评分及BI指数分别为(12.83±2.85)分、(12.83±2.85)和(46.92±6.27)分,均明显优于对照组的(11.04±2.64)分、(16.58±3.15)和(38.68±7.23)分(P<0.05)。观察组治疗总有效率明显高于对照组(50.0%vs.22.5%)(P<0.05)。结论对ACI早期神经功能恶化患者,在常规综合治疗基础上加用醒脑静和依达拉奉治疗能明显改善患者神经功能。

Objective To investigate the efficacy of Xingnaojing combined with edaravone in treating patients with acute cerebral infarction （ACI） and early neurologic deterioration. Methods Eighty ACI patients with early neurological deterioration were equally randomized into two groups of A and B. The patients of two groups were given conventional therapy and those of group A were treated with additional Xingnaojing and edaravone drip for one month. The cerebral function was evaluated using NIHSS scores, Barthel index （B I） and Douglas coma scale （GCS） score. Results Compared to before, the cerebral function was improved significantly after treatment in both groups （P〈0. 05）. The score,NIHSS score and BI in group A were （12. 83±2. 85） points, （12.83± 2. 85） points and （46. 92 ±6.27）, respectively, which were significantly better than （11.04±2. 64） points, （16. 58±3. 15） points and （38.68±7. 23） in group B（P〈0. 05）. The overall effectiveness rate was higher in group A than that in group B（50. 0% vs. 22. 5%）（P〈0. 05）. Conclusion The cerebral function can be improved remarkably by additional treatment with Xingnaojing and edaravone on the basis of conventional therapy in ACI patients with early neurological deterioration.